Texas Weight Loss Program Compliance 2026: GLP-1, Semaglutide & Tirzepatide Rules for Med Spas

The GLP-1 Landscape in Texas Med Spas: What Changed in 2025

For two years, compounded semaglutide was the backbone of weight loss programs at thousands of Texas med spas. When the FDA declared a shortage of semaglutide products in 2022, it opened a legal window for 503A compounding pharmacies to produce copies of the active ingredient. Texas, with its large number of compounding pharmacies and relatively flexible regulatory environment, became one of the biggest markets for compounded GLP-1s.

That window largely closed in 2025. The FDA removed semaglutide from its drug shortage list, which ended the broad exemption that allowed 503A and most 503B pharmacies to compound copies. Texas med spas that had built their weight loss programs around compounded semaglutide were forced to pivot — and many are still figuring out what is still permissible.

The short answer: you can still run a profitable, compliant weight loss program in Texas in 2026. You just need to understand what the rules actually are now.

What Is Still Legal: FDA-Approved GLP-1 Medications

Prescribing FDA-approved GLP-1 receptor agonists is entirely legal and straightforward for properly licensed Texas prescribers. The products currently available include:

• Semaglutide: Ozempic (Type 2 diabetes indication), Wegovy (chronic weight management indication)
• Tirzepatide: Mounjaro (Type 2 diabetes), Zepbound (chronic weight management)
• Liraglutide: Saxenda (weight management), Victoza (diabetes)

A Texas med spa can prescribe any of these to appropriate patients through a licensed prescriber, administer injections via a delegated RN or APRN, and build a complete weight loss program around these branded products. Supply constraints have eased considerably since 2024, and patient assistance programs have improved affordability.

Compounded GLP-1s in 2026: What Remains Permissible

The removal of semaglutide from the shortage list did not make all compounding illegal — it ended the broad exemption. Some narrow pathways remain:

503A Pharmacy Compounding (Patient-Specific)

A Texas State Board of Pharmacy (TSBP)-licensed 503A pharmacy can still compound semaglutide for a specific patient who has a documented allergy or sensitivity to one or more non-active ingredients (excipients) in the commercial product. This requires a valid prescription, documentation of the clinical reason, and a TSBP-licensed pharmacy that is compliant with current FDA guidance on compounding after shortage resolution.

503B Outsourcing Facilities

503B outsourcing facilities face stricter restrictions after the shortage resolution. Most 503B compounders that were producing bulk compounded semaglutide have received FDA warning letters or voluntarily stopped. If your practice was sourcing from a 503B facility, verify their current FDA compliance status before continuing any relationship.

Tirzepatide: Different Status

Tirzepatide's shortage status has followed a different timeline than semaglutide. Practices should check the FDA's current shortage database before making prescribing decisions based on shortage-related compounding permissions, as the status has changed multiple times.

Texas-Specific Prescribing Requirements

Regardless of whether you are using branded or compounded GLP-1 medications, the prescribing framework in Texas must be airtight. The Texas Medical Board has specific prescribing standards that apply:

Establishing a Patient-Prescriber Relationship

Before prescribing any GLP-1 medication, the prescribing provider must establish a legitimate patient-prescriber relationship. In Texas, this means conducting a clinically appropriate patient evaluation — not just reviewing a questionnaire. The evaluation must include an assessment of the patient's medical history, weight history, current medications, contraindications, and clinical appropriateness for GLP-1 therapy.

Who Can Prescribe

GLP-1 medications can be prescribed by:

• Licensed Texas MDs and DOs
• APRNs/NPs with prescriptive authority and an appropriate collaborative practice agreement
• PAs with a supervising physician and TMB-registered supervisory agreement

For more on how prescribing authority works in Texas med spa settings, see our post on Texas med spa medical director requirements.

Telehealth Prescribing

Texas permits telehealth prescribing of GLP-1 medications under 22 TAC §174.6, provided the telehealth encounter constitutes a real clinical evaluation — not just an asynchronous questionnaire. The provider must be licensed in Texas, the evaluation must meet the standard of care for initiating weight loss pharmacotherapy, and the visit must be documented in a medical record accessible to the patient. Texas telehealth rules are more permissive than some states, but they are not a blank check for questionnaire-only prescribing.

TSBP and Compounding Pharmacy Oversight

Texas has its own compounding pharmacy oversight through the Texas State Board of Pharmacy, separate from FDA jurisdiction. Even when FDA has closed a compounding pathway, TSBP may have its own rules — and Texas med spas sourcing from in-state compounders need to verify compliance with both layers of regulation.

Key TSBP requirements relevant to GLP-1 compounding include labeling requirements, beyond-use dating standards, and documentation of the clinical basis for the compounded formulation. A prescription for a compounded GLP-1 without documented clinical justification is a TSBP violation, not just an FDA concern.

Clinical Documentation Requirements

This is where many Texas weight loss programs fall short during TMB reviews. Every patient receiving GLP-1 therapy at your practice should have a chart that includes:

• Baseline weight and BMI — documented at initiation and at each follow-up
• Medical history review — including personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome, which are contraindications for semaglutide and tirzepatide
• Medication review — screening for drug interactions, particularly other diabetes medications
• Metabolic baseline — standard of care includes HbA1c, lipid panel, and metabolic panel at initiation
• Informed consent — covering risks, benefits, off-label use (if applicable), monitoring plan, and what to do if side effects occur
• Monitoring plan — documented follow-up schedule with weight and tolerance check-ins

The quality of your clinical documentation is what separates a compliant Texas weight loss program from one that will not survive a TMB review. See our SOP guide for med spas for how to build documentation templates that hold up to scrutiny.

Administration: Who Can Give the Injections

Once a GLP-1 medication is prescribed, an RN can administer the injection under a physician's written delegation. The administration protocol should cover:

• Injection site selection and rotation
• Dose titration schedule and how changes are authorized
• Adverse event recognition — nausea, vomiting, pancreatitis signs, injection site reactions
• When to hold a dose and escalate to the prescribing physician

For self-injection programs (where patients inject at home), the RN can train patients on technique, but the prescription and monitoring must still be physician-supervised. See our post on who can perform delegated medical acts in Texas for the full delegation framework.

Pricing, Marketing, and FTC Considerations

Weight loss marketing from Texas med spas has attracted FTC attention nationally. Claims like "lose 30 pounds in 30 days" or "guaranteed results" are not only medically inaccurate — they are deceptive trade practice violations. Texas med spa weight loss marketing must:

• Make only claims that are substantiated by clinical evidence
• Disclose that results vary and that medications may not work for all patients
• Not imply that compounded medications are equivalent to FDA-approved branded products
• Comply with TMB advertising rules requiring physician name disclosure

Common Compliance Failures in Texas Weight Loss Programs

Based on TMB review patterns, the most frequent compliance gaps in Texas med spa weight loss programs include:

• Prescribing via online questionnaire without a synchronous patient evaluation
• No documentation of contraindication screening (MTC history, MEN2)
• Sourcing from compounding pharmacies after the shortage exemption ended without verifying continued legal basis
• Inadequate monitoring documentation — no documented weight checks or follow-up plan
• RN administering injections without signed written delegation from physician
• Marketing claims that imply compounded semaglutide is identical to Wegovy/Ozempic

For a full look at what TMB reviewers flag, see our guide to common med spa compliance violations.

Building a Compliant Texas Weight Loss Program in 2026

The practices that are thriving in the post-compounding-exemption environment have made a strategic shift: they compete on the quality of their clinical program, not the price of a compounded product. That means investing in proper patient assessment, monitoring protocols, and physician oversight — which also happens to be exactly what a compliant program looks like.

A well-documented, physician-supervised GLP-1 program using FDA-approved medications with proper RN administration, telehealth follow-ups, and clear monitoring protocols is both legally sound and clinically differentiated from the cut-rate providers that are one audit away from closure.